Allakos
Redwood City
About Allakos
Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos was founded in 2012 and is headquartered in San Carlos, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $312.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2022)
- Ticker: nasdaq:ALLK
- Website: allakos.com
- Phone: 650-597-5002
Industries & Categories
Biopharma, Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/allakos-74319 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.